Your session is about to expire
← Back to Search
hyoscine-n-butylbromide for Ovarian Cancer
Study Summary
This trial will use a novel, high-performance tracer to detect hormone-sensitive uterine and ovarian tumors using PET imaging. This could improve the whole-body assessment of those diseases and help clinicians choose the best course of therapy.
- Ovarian Cancer
- Endometrial Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What ailments is hyoscine-n-butylbromide commonly prescribed for?
"Hyoscine-n-butylbromide can ameliorate ailments ranging from acute biliary spasm, chronic functional diarrhea to muscle tissue related issues."
Are there vacancies for participants in this experiment?
"Affirmative. According to clinicaltrials.gov, this research endeavour has been actively seeking participants since it was posted on September 1st 2018 and last revised October 31st 2022. 72 individuals are needed from a single centre for the trial's completion."
To what extent has participation in this experiment been embraced?
"Indeed, the information hosted on clinicaltrials.gov affirms that this trial is actively recruiting participants since its inception in September 2018 and most recent update in October 2022. 72 volunteers are needed to complete the study conducted at a single site."
Can you provide a summary of the prior studies done with hyoscine-n-butylbromide?
"Currently, 10 research projects exploring hyoscine-n-butylbromide are underway with one in the advanced Phase 3 trials. Initially centered around Nagoya-shi, Aichi, this medication's clinical trial locations have now expanded to 157 sites worldwide."
Is this experiment the inaugural exploration of its kind?
"Currently, 10 active trials dedicated to hyoscine-n-butylbromide are present in 63 cities and 20 countries. This medication was first studied by Eli Lilly and Company back in 2014 with 198 participants and has since completed its Phase 1 drug approval stage. Subsequently, a total of 52 studies have been conducted on the subject matter."
Share this study with friends
Copy Link
Messenger